(Q86408281)

English

Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012

scientific article published on 13 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Valentina Picot

2

object named as

Valentina Picot

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

4

object named as

Gary J Nabel

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Marc P Girard

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Christophe Longuet

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

13 March 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2979-2983

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Prospects of HIV Env modification as an approach to HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Antibody-based protection against HIV infection by vectored immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Pemphigoid diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

The development of CD4 binding site antibodies during HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Elicitation of structure-specific antibodies by epitope scaffolds

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Nonviral delivery of self-amplifying RNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Neutralizing antibodies and control of HIV: moves and countermoves.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.02.068

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q86408281&oldid=1369037274"